Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Prosthesis-patient mismatch after TAVR may not negatively impact quality of life
Researchers warned that “aggressive procedural modifications” should not be necessary during TAVR to mitigate the risk of prosthesis-patient mismatch. This appears to be true for patients receiving both self-expanding and balloon-expandable TAVR valves.
SCAI fighting for interventional cardiologists amid challenging payment policies
SCAI President Srihari Naidu, MD, detailed some of the challenges interventional cardiologists face as reimbursements keep declining. The group has been building new partnerships with other medical societies to strengthen its influence in Washington.
Interventional cardiology showing more interest in endovascular procedures
Sahil Parikh, MD, said it was clear at TCT 2025 that the specialty is getting more and more involved with endovascular procedures for stroke, pulmonary embolism and peripheral artery disease.
CCTA will play an essential role in the cath labs of the future
Noninvasive coronary CT angiography is growing more and more important as time goes on, helping cardiologists make critical treatment decisions. Carlos Collet, MD, PhD, discussed the technique's potential to be a real game-changer for patient care in a new interview.
Transcaval access a safe, effective alternative during Impella implants
In some cases, researchers noted, cardiologists may need to rely on transcaval access during the treatment of a high-risk heart failure patient.

he U.S. Food and Drug Administration (FDA) granted market clearance ion September 2022 for the Edwards Lifesciences Corp. Pascal Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER). It is indicated for the treatment of patients with degenerative mitral regurgitation (DMR).

FDA clears Edwards Pascal device for transcatheter mitral valve repair

This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.

A structural heart Presentation during the TVT 2022 conference. #TCT #TCT22 #TCT2022

TCT 2022 late-breaking clinical presentations announced

The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

SAVR after TAVR is rare, but linked to a high mortality risk

Researchers tracked data from more than 2,000 patients, noting that surgical bailout, infective endocarditis and paravalvular leak were the most common reasons for surgery to be required after TAVR. The full study was published in the American Journal of Cardiology.

TEER safe and feasible for patients with atrial secondary mitral regurgitation

Atrial secondary mitral regurgitation has been linked to higher in-hospital mortality and hospitalization rates.

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation (CRF) and assistant professor of medicine at Columbia University College of Physicians and Surgeons, explains some of the highlights of the upcoming 2022 Transcatheter Cardiovascular Therapies (TCT) conference sponsored by CRF. #TCT #TCT2022

VIDEO: Previewing TCT 2022 in Boston with Juan Granada

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

TAVR patients with CAD face a greater risk of death—is PCI the answer?

All-cause mortality after five years is much more likely if a TAVR patient presents with CAD, according to a new analysis published in JACC: Cardiovascular Interventions.

The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

TAVR's success has changed how cardiologists and surgeons view aortic valve replacement

The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health.

CCTA a helpful tool for interventional cardiologists planning coronary procedures

A new consensus statement from the Society of Cardiovascular Computed Tomography emphasized the increasing importance of CCTA among interventional cardiologists. It is no longer seen as “a mere diagnostic tool," the group observed.

Interventional Cardiology

Prosthesis-patient mismatch after TAVR may not negatively impact quality of life

SCAI fighting for interventional cardiologists amid challenging payment policies

Interventional cardiology showing more interest in endovascular procedures

CCTA will play an essential role in the cath labs of the future

Transcaval access a safe, effective alternative during Impella implants